Reply to "Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?"

CancerVolume 129, Issue 9 p. 1455-1456 REPLY Reply to “Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?” Berthe M. P. Aleman MD, PhD, Corresponding Author Berthe M. P. Aleman MD, PhD [email protected] orcid.org/0000-0003-2306-6590 Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands Correspondence Berthe M. P. Aleman. Email: [email protected]Search for more papers by this authorInge M. Krul MSc, Inge M. Krul MSc orcid.org/0000-0002-2378-5424 Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The NetherlandsSearch for more papers by this authorCécile P. M. Janus MD, Cécile P. M. Janus MD Department of Radiation Oncology, Erasmus University MC Cancer Institute, Rotterdam, The NetherlandsSearch for more papers by this authorRichard W. M. van der Maazen MD, Richard W. M. van der Maazen MD Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The NetherlandsSearch for more papers by this authorFlora E. van Leeuwen PhD, Flora E. van Leeuwen PhD Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The NetherlandsSearch for more papers by this author Berthe M. P. Aleman MD, PhD, Corresponding Author Berthe M. P. Aleman MD, PhD [email protected] orcid.org/0000-0003-2306-6590 Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands Correspondence Berthe M. P. Aleman. Email: [email protected]Search for more papers by this authorInge M. Krul MSc, Inge M. Krul MSc orcid.org/0000-0002-2378-5424 Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The NetherlandsSearch for more papers by this authorCécile P. M. Janus MD, Cécile P. M. Janus MD Department of Radiation Oncology, Erasmus University MC Cancer Institute, Rotterdam, The NetherlandsSearch for more papers by this authorRichard W. M. van der Maazen MD, Richard W. M. van der Maazen MD Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The NetherlandsSearch for more papers by this authorFlora E. van Leeuwen PhD, Flora E. van Leeuwen PhD Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The NetherlandsSearch for more papers by this author First published: 24 February 2023 https://doi.org/10.1002/cncr.34713 See correspondence on pages 1453–4, this issue. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Krul IM, Boekel NB, Kramer I, et al. Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma. Cancer. 2022; 128(24): 4285-4295. doi:10.1002/cncr.34464 2Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med. 2015; 373(26): 2499-2511. doi:10.1056/nejmoa1505949 3Milgrom SA, Bakst RL, Campbell BA. Clinical outcomes confirm conjecture: modern radiation therapy reduces the risk of late toxicity in survivors of Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2021; 111(4): 841-850. doi:10.1016/j.ijrobp.2021.06.030 4Eichenauer DA, Aleman BMP, Andre M, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(suppl 4): iv19-iv29. 5Follows GA, Barrington SF, Bhuller KS, et al. Guideline for the first-line management of classical Hodgkin lymphoma—a British Society for Haematology guideline. Br J Haematol. 2022; 197(5): 558-572. doi:10.1111/bjh.18083 6Wirth A, Mikhaeel NG, Aleman BMP, et al. Involved site radiation therapy in adult lymphomas: an overview of International Lymphoma Radiation Oncology Group guidelines. Int J Radiat Oncol Biol Phys. 2020; 107(5): 909-933. doi:10.1016/j.ijrobp.2020.03.019 7van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015; 175(6): 1007-1017. doi:10.1001/jamainternmed.2015.1180 8Jones DA, Candio P, Shakir R, et al. Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry. Blood Adv. 2022; 6(3): 909-919. doi:10.1182/bloodadvances.2021006254 9de Vries S, Haaksma ML, Jozwiak K, et al. Development and validation of risk prediction models for coronary heart disease and heart failure after treatment for Hodgkin lymphoma. J Clin Oncol. 2023; 41(1): 86-95. doi:10.1200/jco.21.02613 Volume129, Issue91 May 2023Pages 1455-1456 ReferencesRelatedInformation